zurück Home	Prospective studies on stereotactic radiotherapy for primary renal tumors
Allgemeines
Operation	Autor Phase Zeit Patienten Fraktionierung Follow-up LV OS Technik Toxizität Bemerkungen Kaplan et al. (abstract only) [19] Phase I 2006–2009 N = 12, medically inoperable 3 × 7–13 Gy,tumors 5 cm (isodose not reported) Not reported 83 % Not reported Robotic radiosurgery, respiratory motion tracking No relevant toxicity Pham et al. [20] Phase I 2012–2013 N = 20, median age 77, primary inoperable RCC 3 × 14 Gy (tumor ≥ 5 cm), 1 × 26 Gy (<5 cm) to 75–85 % isodose Not reported Not reported Not reported 3DCRT with a median of 8 beams; 4D-CT, ITV concept 60 % grade 1–2 Ponsky et al. [22] Phase I 2006–2011 N = 19, median age 77, medically inoperable 4 × 6–12 Gy to 65–75 % isodose, 3 fractions/week 13.7 months Stable disease at 6 months in all evaluable patients Not reached; 3-year OS 72 % Robotic radiosurgery, respiratory motion tracking 5 % grade 2, 11 % grade 3 worsening of renal function, 5 % grade 4 (duodenal ulcer) Svedmanet al. [23] Phase II 1999–2004 N = 5 pts. with inoperable tumor, 25 metastatic pts 2–5 × 5–15 Gy, most commonly 4 × 10 Gy to the PTV margin (no isodose reported) 52 months for patients alive, 22 for deceased patients 98 % for all lesions 32 months for all patients 3DCRT 5 to 8 static beams, stereotactic body frame 57 % grade 1–2 Staehler et al. [17] Phase II 2007–2011 N = 40, median age 64, transitional cell cancer in 15 pts 1 × 25 Gy to 70 % isodose 28 months 98 % at 9 months Not yet reached Robotic radiosurgery, respiratory motion tracking 18 % grade 1–2; stable renal function in all pts RCC renal cell carcinoma, OS overall survival, 3DCRT three-dimensional conformal radiotherapy, ITV internal target volume, pts. Patients, PTV planning target volume Strahlenther Onkol (2016) 192:875–885 Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer Dr.med. Cédric Panje, DOI 10.1007/s00066-016-1053-1
Quellen	17. Staehler M, Bader M, Schlenker B et al (2015) Single fraction ra- diosurgery for the treatment of renal tumors. J Urol 193:771–775. doi:10.1016/j.juro.2014.08.044 18. Siva S, Pham D, Gill S et al (2012) A systematic review of stereo- tactic radiotherapy ablation for primary renal cell carcinoma. BJU Int 110:E737–E743. doi:10.1111/j.1464-410X.2012.11550.x 19. Kaplan ID, Redrosa I, Martin C et al (2010) Results of a phase I dose escalation study of stereotactic radiosurgery for primary renal tumors. Int J Radiat Oncol 78:S191. doi:10.1016/j.ijrobp.2010.07. 464 20. Pham D, Thompson A, Kron T et al (2014) Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys 90:1061–1068. doi:10.1016/j.ijrobp. 2014.07.043 21. Siva S, Jackson P, Kron T et al (2016) Impact of stereotac- tic radiotherapy on kidney function in primary renal cell carci- noma: Establishing a dose-response relationship. Radiother Oncol 118:540–546. doi:10.1016/j.radonc.2016.01.027 22. Ponsky L, Lo SS, Zhang Y et al (2015) Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol 117:183–187. doi:10.1016/j.radonc.2015.08.030 23. Svedman C, Sandström P, Pisa P et al (2006) A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45:870–875. doi:10. 1080/02841860600954875
wichtiger Hinweis!	Für die Richtigkeit von Dosisangaben, Zielvolumina und Indikationen kann keine Garantie übernommen werden. In Zweifelsfällen sind die aktuellen nationalen und internationalen Leitlinien einzusehen.

Impressum                                 Zuletzt geändert am 16.10.2022 6:08